Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Fabio Guolo; Claudio Cerchione; Chiara Vernarecci; Alessandro Isidori

doi:10.3389/fonc.2022.1020185

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Front Oncol. 2022 Sep 9:12:1020185. doi: 10.3389/fonc.2022.1020185. eCollection 2022.

Authors

Fabio Guolo^{1

2}, Claudio Cerchione³, Chiara Vernarecci¹, Alessandro Isidori⁴

Affiliations

¹ Clinic Of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy.
² Dipartimento di Oncologia ed Ematologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
³ Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy.
⁴ Haematology and Stem Cell Transplant Center, Azienda Ospedaliera Ospedali Riuniti Marche Nord (AORMN), Pesaro, Italy.

No abstract available

Keywords: acute myeloid leukemia (AML); allogeneic stem cell transplantation; immunotherapy; leukemic stem cell (LSC); minimal residual disease (MRD).

Publication types

Editorial